How we handle corrections
Every article cites its sources, and we check those references against their PubMed records. When a claim does not match its source, we correct the claim, change the source or remove the claim. Substantive corrections, meaning changes to a fact, a figure, a recommendation or a source, are listed below with the date of the fix. How we check sources is described in our methodology. If you spot an error, please tell us through our contact page.
Sitewide corrections
- September 30 to October 1, 2026Re-checked every printed reference against its PubMed record, corrected wrong details, fixed 26 references that pointed at the wrong paper and replaced a retracted study.
- September 30, 2026Removed an invented timeline of research results, including trial results that do not exist, from 19 pages and replaced it with verified milestones.
- September 30, 2026Removed 12 studies from the Research Radar that we could not verify, along with their mentions in three tools. The Research Radar page is no longer indexed.
- September 30 to October 1, 2026Deleted 26 quotes attributed to named scientists that we could not source.
- October 1, 2026Every article now cites its sources: we added references, each checked against its PubMed record, to every article that lacked them.
- October 1, 2026Rebuilt the supplement interaction checker: removed 16 interactions without solid evidence and re-sourced the remaining 16, each linked to its research.
- October 1, 2026Relabelled the biological age questionnaire as an unvalidated lifestyle estimate (it had claimed to be derived from the PhenoAge model) and added a PhenoAge calculator that follows the published model.
- October 1, 2026Removed three charts whose numbers we could not source and redrew the sleep-and-mortality chart from its source.
- October 1, 2026Checked all 148 glossary definitions against published research and rewrote 113 of them: removed a clinical trial that does not exist, "optimal" lab ranges that no study supports and outdated claims (for example, that kidney-function equations use race). Each definition now links to its source.
- October 1, 2026Rebuilt the lab results interpreter and the biomarker guide. Both had graded results against "optimal" ranges that no guideline supports (for example, HbA1c below 5.3% or vitamin D of 40 to 60 ng/mL) and used made-up grading rules. They now use the categories in clinical guidelines and NIH references, cite every cut-off, and say when a marker has no agreed range.
- October 1, 2026Rebuilt the blood panel builder and the test guide. They had listed unverified lab order codes (one was the wrong test), exact prices that decided which tests you saw, invented "optimal" ranges and testing schedules that contradicted guidelines. They now suggest tests by scope and risk, follow published screening recommendations (for example, colorectal screening from 45 and bone density screening for women from 65), and cite their sources.
- October 1, 2026Regraded the supplement evidence database and the longevity stack builder. Fish oil, vitamin D, niacin and magnesium had been graded A despite large trials finding no prevention benefit (VITAL, ASCEND) or, for niacin added to statins, no benefit and more side effects (AIM-HIGH, HPS2-THRIVE). Every grade now names the outcome it applies to, every listed study links to its PubMed record, and citations that could not be found or matched the wrong paper were removed. The stack builder's score is now an average, so adding weakly supported items lowers it, and its invented popularity percentages were removed.
Page corrections
- October 1, 2026Grounding review: Removed a "2025 South Korean trial" that does not exist; it had been presented as the main evidence.
- October 1, 2026Budget longevity protocol: Removed a default of 5,000 IU of vitamin D a day for everyone, which is above the 4,000 IU upper limit; vitamin D advice now follows the Endocrine Society's 2024 guideline. Corrected the claim that creatine protects bone.
- October 1, 2026Longevity protocol by age: Reversed the claim that CoQ10 is strongly recommended with statins (a meta-analysis found no benefit) and removed recommendations for MTHFR testing and whole-body MRI screening.
- October 1, 2026Protocol for men with low testosterone: Removed claims that testosterone therapy improves cognition and that vitamin D raises testosterone; trials found neither.
- October 1, 2026Protocol for post-menopausal women: Corrected bone-loss figures and aligned hormone therapy guidance with the 2022 menopause society position statement.
- October 1, 2026Heart disease protocol: Corrected the blood pressure effect of magnesium (about 2 mmHg) and the evidence on colchicine.
- October 1, 2026Type 2 diabetes protocol: Corrected the effect of walking after meals and cardiovascular risk figures, and removed claims that several supplements lower blood sugar.
- October 1, 2026Chronic kidney disease protocol: Corrected kidney-disease risk figures and set protein targets to the KDIGO 2024 guideline.
- October 1, 2026Thyroid protocol: Removed unsupported "optimal" TSH and free T3 targets.
- October 1, 2026Fatty liver protocol: Corrected the cardiovascular risk figure and the claim that time-restricted eating helps independently of calories.
- October 1, 2026PCOS protocol: Corrected cardiovascular risk claims and the strength of the evidence for inositol.
- October 1, 2026Protocol after cancer: Corrected vitamin D claims: the trials did not show lower cancer recurrence.
- October 1, 2026Anxiety and depression protocol: Removed claims that some supplements work as well as SSRIs.
- October 1, 2026ADHD protocol: Removed advice to take stimulant medication with antacids, which can raise amphetamine levels.
- October 1, 2026Autoimmune disease protocol: Corrected the VITAL trial result and removed high-dose vitamin D advice.
- October 1, 2026Chronic pain and fibromyalgia protocol: Corrected claims about low-dose naltrexone, vitamin D and creatine for pain.
- October 1, 2026Supplement interactions: Corrected an overstated berberine and metformin risk and other interaction claims.
- October 1, 2026Fasting insulin and HOMA-IR: Removed "longevity-optimal" targets that no study supports.
- October 1, 2026Sauna and longevity: Corrected the mortality figures, the length of follow-up and a growth hormone claim to match the studies.
- October 1, 2026NAD+ and sirtuins: Corrected the description of the main NMN trial: it studied women with prediabetes, not older men.
- October 1, 2026Rapamycin and mTOR: Clarified that the 9% and 14% mouse results measured maximum lifespan, not median lifespan.
- October 1, 2026Is rapamycin safe?: Corrected statements that the PEARL trial's results were still pending.
- October 1, 2026Psychedelic medicine: Added the FDA's 2024 decision not to approve MDMA-assisted therapy and corrected trial details for MDMA and psilocybin.
- October 1, 2026Longevity genomics: Updated the genetic share of lifespan (well below 10% in the largest analysis) and cancer-gene risk figures.
- October 1, 2026Omega-3 fatty acids: Corrected a citation that credited a 2018 analysis with trials published later, and the typical US omega-3 level.
- October 1, 2026Protein and longevity: Corrected protein advice for adults over 65 to the expert recommendation of at least 1.0 to 1.2 g/kg a day.
- October 1, 2026Zone 2 training: Removed unsupported minimum-dose claims and a claim that Zone 2 training outperformed metformin.
- October 1, 2026Testosterone and TRT: Corrected the age-related decline figures and TRAVERSE trial details, and removed dosing specifics the sources do not support.
- October 1, 2026Red light therapy: Corrected the list of uses endorsed by the 2025 dermatology consensus and removed an inaccurate NASA story.
- October 1, 2026Exosomes: Corrected the description of the FDA's 2019 safety notice.
- October 1, 2026FDA peptide reclassification: Corrected the status of Melanotan II, which left the FDA's restricted list in April 2026.
- October 1, 2026GLP-1 agonists: Restated a "proven" mortality claim as the actual trial results.
- October 1, 2026Longevity for women: Corrected hormone therapy and cardiovascular timing claims.
- October 1, 2026The longevity supplements guide: Corrected what the VITAL trial showed and removed an unsourced market figure.
- October 1, 2026Course: Optimize Your Bloodwork: Replaced "longevity-optimal" lab ranges with guideline categories, corrected an Lp(a) unit error and a vitamin D example that contradicted NIH guidance, and fixed a statistic that mixed up two studies.
- October 1, 2026Course: Longevity Fundamentals: Replaced invented "optimal" targets in the biomarker lesson with guideline categories.
- October 1, 2026Menopause biomarker tracking guide: Replaced invented "optimal" ranges with guideline and reference categories, and corrected testing advice that contradicted the Endocrine Society and US Preventive Services Task Force.